Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 862 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy MOST POPULAR Lessons from the green: How sports psychology helped a top golf... March 16, 2023 PICOS Score May Help in Identification of Patients with Brain Metastasis... June 24, 2020 COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... September 13, 2020 Cancer and the Holidays December 3, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Enzalutamide Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... Discovering the BRCA2 gene – 25 years on
